| Literature DB >> 34073129 |
Iriny M Ayoub1, Michal Korinek2,3,4,5, Mohamed El-Shazly1,6, Bernhard Wetterauer7, Hesham A El-Beshbishy8,9, Tsong-Long Hwang4,5,10, Bing-Hung Chen3, Fang-Rong Chang2,11,12,13, Michael Wink7, Abdel Nasser B Singab1,14, Fadia S Youssef1.
Abstract
This study aims to comprehensively explore the phytoconstituents as well as investigate the different biological activities of Chasmanthe aethiopica (Iridaceae) for the first time. Metabolic profiling of the leaf methanol extract of C. aethiopica (CAL) was carried out using HPLC-PDA-ESI-MS/MS. Twenty-nine compounds were annotated belonging to various phytochemical classes including organic acids, cinnamic acid derivatives, flavonoids, isoflavonoids, and fatty acids. Myricetin-3-O-rhamnoside was the major compound identified. GLC/MS analysis of the n-hexane fraction (CAL-A) resulted in the identification of 45 compounds with palmitic acid (16.08%) and methyl hexadecanoic acid ester (11.91%) representing the major constituents. CAL-A exhibited a potent anti-allergic activity as evidenced by its potent inhibition of β-hexosaminidase release triggered by A23187 and IgE by 72.7% and 48.7%, respectively. Results were comparable to that of dexamethasone (10 nM) in the A23187 degranulation assay showing 80.7% inhibition for β-hexosaminidase release. Both the n-hexane (CAL-A) and dichloromethane (CAL-B) fractions exhibited potent anti-inflammatory activity manifested by the significant inhibition of superoxide anion generation and prohibition of elastase release. CAL showed anti-hyperglycemic activity in vivo using streptozotocin-induced diabetic rat model by reducing fasting blood glucose levels (FBG) by 53.44% as compared with STZ-treated rats along with a substantial increase in serum insulin by 22.22%. Molecular modeling studies indicated that dicaffeoylquinic acid showed the highest fitting with free binding energies (∆G) of -47.24 and -60.50 Kcal/mol for human α-amylase and α-glucosidase, respectively confirming its anti-hyperglycemic activity. Thus, C. aethiopica leaf extract could serve as an effective antioxidant natural remedy combating inflammation, allergy, and hyperglycemia.Entities:
Keywords: Chasmanthe aethiopica; GC/MS; LC/MS; anti-allergic; anti-inflammatory; antihyperglycemic
Year: 2021 PMID: 34073129 PMCID: PMC8226651 DOI: 10.3390/plants10061118
Source DB: PubMed Journal: Plants (Basel) ISSN: 2223-7747
Figure 1GLC-chromatogram of C. aethiopica L. n-hexane fraction (CAL-A) on Rtx-5MS column.
Chemical profile of C. aethiopica L. n-hexane fraction (CAL-A) by GLC-MS.
| No. | Rt | Compound Name | RIExp.
| RILit
| Content% | Molecular Formula | Identification |
|---|---|---|---|---|---|---|---|
| 1. | 31.44 | Methyl pentadecanoic acid ester | 1806 | 1812 | 0.15 | C16H32O2 | MS, RI |
| 2. | 31.68 | Neophytadiene | 1818 | 1817 | 0.50 | C20H38 | MS, RI |
| 3. | 31.85 | Hexahydrofarnesyl acetone | 1826 | 1825 | 5.30 | C18H36O | MS, RI |
| 4. | 33.47 | 7-Hexadecenoic acidmethyl ester (Z) | 1903 | 1900 | 0.68 | C17H34O2 | MS, RI |
| 5. | 33.54 | Hexadecanoic acid methyl ester | 1907 | 1907 | 11.91 | C17H34O2 | MS, RI |
| 6. | 34.45 | Palmitic acid | 1950 | 1950 | 16.08 | C16H32O2 | MS, RI |
| 7. | 34.99 | Heptadecanoic acid methyl ester | 1976 | 1978 | 0.14 | C18H36O2 | MS, RI |
| 8. | 35.55 | 15-Methyl hexadecanoic acid methyl ester | 2003 | 1996 | 0.52 | C18H36O2 | MS, RI |
| 9. | 36.77 | 16-Methyl heptadecanoic acid methyl ester | 2070 | 2077 | 0.25 | C19H38O2 | MS, RI |
| 10. | 36.90 | Linoleic acid methyl ester | 2077 | 2075 | 2.42 | C19H34O2 | MS, RI |
| 11. | 37.03 | Oleic acidmethyl ester | 2085 | 2085 | 4.10 | C19H36O2 | MS, RI |
| 12. | 37.25 | Phytol | 2096 | 2096 | 1.50 | C20H40O | MS, RI |
| 13. | 37.48 | Methyl stearate | 2109 | 2109 | 2.08 | C19H38O2 | MS, RI |
| 14. | 37.89 | Linolenic acid | 2131 | 2134 | 3.74 | C18H30O2 | MS, RI |
| 15. | 38.24 | Stearic acid | 2150 | 2155 | 0.83 | C18H36O2 | MS, RI |
| 16. | 41.08 | Eicosanoic acid methyl ester | 2306 | 2307 | 0.57 | C21H42O2 | MS, RI |
| 17. | 41.62 | 4,8,12,16-Tetramethylheptadecan-4-olide | 2336 | 2364 | 1.99 | C21H40O2 | MS |
| 18. | 42.84 | 2,2′-Methylene-bis-(6-tert butyl-4-methylphenol) | 2403 | 2398 | 0.13 | C23H32O2 | MS, RI |
| 19. | 43.86 | 2469 | 2500 | 1.46 | C25H52 | MS | |
| 20. | 44.22 | Palmitic acid | 2492 | 2498 | 0.16 | C19H38O4 | MS, RI |
| 21. | 44.41 | Docosanoic acid methyl ester | 2504 | 2492 | 0.40 | C23H46O2 | MS, RI |
| 22. | 45.44 | 11-Methylpentacosane | 2570 | 2565 | 1.99 | C26H54 | MS, RI |
| 23. | 45.97 | Tricosanoic acid methyl ester | 2605 | 2615 | 0.05 | C24H48O2 | MS, RI |
| 24. | 46.95 | 2-Methylhexacosane | 2668 | 2663 | 2.41 | C27H56 | MS, RI |
| 25. | 47.49 | Tetracosanoic acid methyl ester | 2702 | 2714 | 0.14 | C25H50O2 | MS, RI |
| 26. | 48.42 | 2-Methylheptacosane | 2762 | 2762 | 2.47 | C28H58 | MS |
| 27. | 49.43 | 2827 | 2860 | 4.13 | C29H50O4 | MS | |
| 28. | 49.74 | 2847 | 2881 | 4.62 | C29H50O4 | MS | |
| 29. | 49.83 | 2-Methyl octacosane, | 2852 | 2857 | 3.57 | C29H60 | MS, RI |
| 30. | 50.20 | Cholesta-2,4-diene | 2876 | 2872 | 0.09 | C27H44 | MS, RI |
| 31. | 51.19 | 15-Methylnonacosane | 2940 | 2935 | 2.05 | C30H62 | MS, RI |
| 32. | 52.51 | 3025 | 3003 | 2.02 | C30H62 | MS, RI | |
| 33. | 52.94 | 3053 | - | 1.77 | C32H54O2 | MS | |
| 34. | 53.31 | 3076 | 3112 | 1.76 | C29H50O2 | MS | |
| 35. | 53.84 | Hentriacontane | 3110 | 3103 | 1.33 | C31H64 | MS, RI |
| 36. | 55.31 | Dotriacontane | 3205 | 3202 | 0.64 | C32H66 | MS, RI |
| 37. | 56.36 | Chondrillasterol | 3272 | 3295 | 1.54 | C29H48O | MS, RI |
| 38. | 57.16 | 3323 | 3337 | 0.42 | C30H50O | MS, RI | |
| 39. | 57.43 | 3341 | 3351 | 0.17 | C29H50O | MS, RI | |
| 40. | 58.06 | 3381 | 3376 | 1.53 | C30H50O | MS, RI | |
| 41. | 58.23 | Stigmasta-3,5-dien-7-one | 3392 | - | 0.29 | C29H46O | MS |
| 42. | 59.07 | 3446 | 3438 | 0.76 | C32H52O2 | MS, RI | |
| 43. | 60.05 | Lupeol acetate | 3509 | 3525 | 0.64 | C32H52O2 | MS, RI |
| 44. | 60.42 | Hexadecanoic acid, 3,7,11,15-tetramethyl-2-hexadecenyl ester | 3533 | 3568 | 2.32 | C36H70O2 | MS, RI |
| Total identified (%) | 91.62 |
Retention index determined experimentally on RTX-5MS column relative to n-alkane series (C8–C28), Published retention indices, Identification was based on comparison of mass spectral data (MS) and retention indices (RI) with those of NIST Mass Spectral Library (2017), Wiley Registry of Mass Spectral Data 8th edition and literature.
Figure 2HPLC-ESI-MS base peak chromatogram of C. aethiopica leaf total methanol extract in the negative ion mode.
Metabolite profiling of C. aethiopica leaf total methanol extract via HPLC-PDA-ESI-MS/MS in the positive and negative ion mode.
| Peak No. | Name | UV | [M − H]+ | [M − H]− ( | MS2 | Molecular Formula | References | |
|---|---|---|---|---|---|---|---|---|
| 1. | 2.59 | Quinic acid | 274 | 191 | 173, 127, 85 | C7H12O6 | [ | |
| 2. | 5.09 | Phenyl alanine | 252, 275 | 166 | 164 | 147, 119 | C9H11NO2 | [ |
| 3. | 5.75 | Protocatechuic acid | 254, 286 | 153 | 109 | C7H6O4 | [ | |
| 4. | 7.21 | Dicaffeoyl quinic acid | 269, 310 | 515 | 353, 341, 323, 191, 179 | C25H24O12 | [ | |
| 5. | 7.54 | Dicaffeoyl quinic acid isomer | 282, 310 | 515 | 353, 341, 323, 191, 179 | C25H24O12 | [ | |
| 6. | 7.65 | Hydroxy-methoxy acetophenone- | 283 | 327 | 295, 283, 179, 165,147, 119 | C15H20O8 | [ | |
| 7. | 8.07 | Caffeoylquinic acid | 289, 322 | 353 | 191, 179, 135 | C16H18O9 | [ | |
| 8. | 9.24 | Caffeoylquinic acid isomer | 288, 315 | 353 | 191, 179, 135 | C16H18O9 | [ | |
| 9. | 9.88 | Myricetin- | 270, 316 | 625 | 479, 478, 463, 317, 271, 179 | C30H26O15 | [ | |
| 10. | 10.34 | Iristectorin A/B | 265 | 491 | 473, 447, 401, 371, 343, 329, 311, 283, 241, 191, 146, | C23H24O12 | [ | |
| 11. | 11.12 | Myricetin- | 263, 311 | 625 | 479, 478, 463, 317, 287, 271 | C30H26O15 | [ | |
| 12. | 11.75 | Tricin- | 264, 310 | 477 | 475 | 329, 328, 315, 299 | C23H24O11 | [ |
| 13. | 13.33 | Trihydroxy-dimethoxy-flavone- | 265, 310 | 477 | 475 | 457, 447, 431, 329, 328, 301, 175, 145 | C23H24O11 | [ |
| 14. | 14.21 | Hexahydroxy-isoflavone- | 264, 322 | 479 | 461, 433, 389, 359, 317, 316, 271, 151 | C21H20O13 | [ | |
| 15. | 14.92 | Myricetin-3- | 255, 346 | 465 | 463 | 317, 316, 287, 271, 262, 179, 151 | C21H20O12 | [ |
| 16. | 15.36 | Myricetin | 255, 350 | 319 | 319, 301, 273, 263, 165, 179, 153, 109 | C15H10O8 | [ | |
| 17. | 15.87 | Tetrahydroxy dimethoxy isoflavone- | 234, 270, 311 | 509 | 507 | 489, 476, 475, 463, 345, 329, 301, 273, 191, 175 | C23H24O13 | [ |
| 18. | 17.19 | 6-Hydroxyluteolin 7- | 316 | 447 | 301 | C21H20O11 | [ | |
| 19. | 17.46 | 6-Hydroxy luteolin | 234, 315 | 303 | 303, 285, 257, 165, 153, 137 | C15H10O7 | [ | |
| 20. | 17.75 | Myricetin- | 316 | 773 | 771 | 625, 463, 317 | C36H36O19 | [ |
| 21. | 23.20 | 5,4′-Dihydroxy-3′-methoxy-6,7-methylenedioxy isoflavone (Iriflogenin) | 276 | 327 | 309, 291, 283, 180, 165, 137 | C17H12O7 | [ | |
| 22. | 23.73 | Dihydroxy-methoxy-6,7-methylenedioxy isoflavone | 276 | 327 | 309, 291, 283, 229, 179, 165 | C17H12O7 | [ | |
| 23. | 29.14 | Dihydroxy-23-oxo-12-oleanen-28-oic acid- | 275 | 941 | 779, 617, 485 | C48H77O18 | [ | |
| 24. | 29.41 | Dihydroxy-octadecadienoic acid | 274 | 311 | 293, 267, 171, 153 | C18H32O4 | [ | |
| 25. | 35.93 | Hydroxy octadecatrienoic acid | 276 | 293 | 275, 249, 211, 183, 171, 121 | C18H30O3 | [ | |
| 26. | 38.45 | Hydroxy octadecadienoic acid | 277 | 295 | 277, 251, 211, 195, 183, 171 | C18H32O3 | [ | |
| 27. | 41.33 | Hydroxy octadecenoic acid | 276 | 297 | 279, 253, 171 | C18H34O3 | [ | |
| 28. | 48.29 | Hydroxyhexadecanoic acid (Hydroxy-palmitic acid) | Nd | 271 | 253, 225, 210 | C16H32O3 | [ | |
| 29. | 54.51 | Hydroxyoctadecanoic acid (Hydroxy-stearic acid) | Nd | 299 | 253 | C18H36O3 | [ |
Figure 3Major compounds identified in C. aethiopica leaf total methanol extract using HPLC-ESI-MS in the negative ion mode.
Anti-allergic effects of C. aethiopica leaf total methanol extract and its fractions at different concentrations using degranulation assay in RBL-2H3 cell line.
| Sample | Inhibition % of A23187-Induced | Inhibition % of Antigen-Induced | ||||||
|---|---|---|---|---|---|---|---|---|
| 1 μg/mL | 10 μg/mL | 100 μg/mL | 200 μg/mL | 1 μg/mL | 10 μg/mL | 100 μg/mL | 200 μg/mL | |
| CAL | NS c | TOX d | TOX d | TOX d | NS c | TOX d | TOX d | TOX d |
| CAL-A | NS b | 8.0 ± 4.9 | 41.3 ± 5.4 *** | 72.7 ± 2.2 ***e | NS b | 4.0 ± 1.7 | 12.0 ± 5.2 | 48.7 ± 8.6 *** |
| CAL-B | NS c | TOX d | TOX d | TOX d | NS c | TOX d | TOX d | TOX d |
| CAL-C | NS c | TOX d | TOX d | TOX d | NS c | TOX d | TOX d | TOX d |
| CAL-D | NS c | TOX d | TOX d | TOX d | NS c | TOX d | TOX d | TOX d |
| CAL-E | NS c | TOX d | TOX d | TOX d | NS c | TOX d | TOX d | TOX d |
CAL: C. aethiopica leaf total methanol extract; CAL-A: C. aethiopica n-hexane fraction; CAL-B: C. aethiopica dichloromethane fraction; CAL-C: C. aethiopica ethyl acetate fraction; CAL-D: C. aethiopica n-butanol fraction; CAL-E: C. aethiopica remaining aqueous fraction. a Results are presented as mean ± S.E.M. value (n = 3). *** p < 0.001 compared with the control value (A23187 or antigen only). Dexamethasone, a positive control, inhibited 80.7 ± 3.8% (A23187-induced) and 79.7 ± 2.5% (antigen-induced) degranulation at a concentration of 10 nM. b NS: Not significant inhibition (degranulation more than 85 % of control) (n = 1). c NS: Not significant inhibition (degranulation more than 85 % of control) (n = 2). d TOX: toxic (viability less than 80% of control). e CAL-A inhibited A23187-induced β-hexosaminidase release with IC50 127.7 μg/mL.
Inhibitory effects of C. aethiopica leaf total methanol extract and its fractions on superoxide anion generation and elastase release in FMLF/CB-induced human neutrophils.
| Sample | Superoxide Anion | Elastase Release | ||
|---|---|---|---|---|
| IC50 (μg/mL) a | Inhibition% | IC50 (μg/mL) a | Inhibition% | |
|
| >10 | 36.45 ± 2.58 *** | >10 | 15.27 ± 2.13 ** |
|
|
| 68.68 ± 3.87 *** |
| 65.18 ± 6.81 *** |
|
|
| 58.31 ± 3.76 *** |
| 68.08 ± 7.25 *** |
|
| >10 | 43.84 ± 1.94 *** | >10 | 24.51 ± 4.05 ** |
|
| >10 | 22.47 ± 5.53 * | b | b |
|
| >10 | 26.49 ± 2.73 *** | >10 | 5.30 ± 2.67 |
CAL: C. aethiopica leaf total methanol extract; CAL-A: C. aethiopica n-hexane fraction; CAL-B: C aethiopica dichloromethane fraction; CAL-C: C. aethiopica ethyl acetate fraction; CAL-D: C. aethiopica n-butanol fraction; CAL-E: C. aethiopica remaining aqueous fraction. a Percentage of inhibition at 10 μg/mL concentration. Results are presented as mean ± S.E.M. (n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001 compared with the control value (fMLF/CB). b Sample CAL-D had promoting effects (23.86 ± 3.78% in the presence of CB) on elastase release in human neutrophils.
Effect of C. aethiopica leaf total methanol extract (CAL) at concentrations of 30 and 50 μg/mL on glucose consumption in media of 3T3-L1 adipocyte cultures.
| Glucose Concentration in mmol/L | ||
|---|---|---|
| 30 μg/mL | 50 μg/mL | |
|
| 22.9 ± 0.7 | 21.10 ± 0.6 * |
|
| 22.4 ± 0.4 * | 21.56 ± 0.7 * |
|
| 22.8 ± 0.9 | 22.6 ± 0.1 * |
|
| 23.9 ± 0.7 | 24.1 ± 0.6 |
|
| 25.3 ± 0.6 | 25.0 ± 0.6 |
Data are measured in triplicates (n = 3) and presented as means ± SEM. * Significantly different from the untreated control group at p < 0.05.
Figure 4Effect of intraperitoneal injection of 20 mg/kg/day of C. aethiopica leaf total methanol extract (CAL) and 600 μg/kg/day glibenclamide (GLB) on FBG (A) and serum insulin (B) levels in STZ-induced diabetic rats. Data are measured in triplicates (n = 3) and presented as means ± S.E.M. * Significantly different from the STZ-treated group at p < 0.05; FBG was assessed using a glucose oxidase kit; serum insulin was determined by an immunoassay kit.
Free binding energies (∆G) of the major identified compounds with human α-amylase (HA) and human α-glucosidase (HG) enzymes active centers using molecular docking with pH- and rule-based methods and expressed in kcal/mol.
| Compound | Human | Human | ||
|---|---|---|---|---|
| pH-Based | Rule-Based | pH-Based | Rule-Based | |
| Quinic acid | −15.49 | −15.49 | −15.23 | −15.23 |
| Phenyl alanine | −32.81 | −32.81 | −28.53 | −28.53 |
| Protocatecheuic acid | −31.44 | −31.40 | −31.84 | −31.80 |
| Dicaffeoylquinic acid | −47.24 | −47.24 | −60.50 | −60.50 |
| Caffeoyl quinic acid | −38.43 | −38.43 | −37.68 | −37.68 |
| Iristectorin | −4.17 | −4.17 | −14.84 | −14.84 |
| Myricetin-3- | −26.44 | −21.14 | −27.30 | −22.92 |
| Myricetin | −44.05 | −41.05 | −45.83 | −41.82 |
| 6-Hydroxyluteolin 7- | −39.66 | −20.66 | −45.68 | −23.64 |
| 6-Hydroxyluteolin | −33.45 | −21.66 | −36.10 | −23.82 |
| Iriflogenin | −11.57 | −11.57 | −13.41 | −13.41 |
| Dihydroxy-linoleic acid | −23.28 | −23.28 | −29.60 | −29.60 |
| Hydroxy-linolenic acid | −3.89 | −3.69 | 0.17 | 0.12 |
| Hydroxy-oleic acid | −32.61 | −32.61 | −35.86 | −35.86 |
| Hydroxy-stearic acid | −44.62 | −44.62 | −52.17 | −52.17 |
| Hydroxy-palmitic acid | −44.62 | −44.62 | −48.43 | −48.43 |
| Acarbose | −76.29 | −76.29 | −89.19 | −89.19 |
Figure 52D and 3Dbinding modes of dicaffeoylquinic acid (A) and acarbose (B) within human amylase (HA) active centers employing C-docker protocol.
Figure 62D and 3D binding modes of dicaffeoylquinic acid (A) and acarbose (B) within human glucosidase (HG) active centers employing C-docker protocol.